6 minute read
Dec. 18, 2023
JT001: Jecure’s Early, Acquired NLRP3 Inhibitor with an Unexpected Toxicity
JT001
NLRP3 inflammasome inhibitor oral efficacy in models; related to Ph. I candidate GDC-2394 from MCC950 and opt. for lipophilic ligand efficacy J. Pharmacol. Exp. Ther., August 1, 2023 Jecure / Genentech, CA
Author:
Editor:
Loading...
